A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Gefitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2011 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov record.
- 06 Apr 2010 Actual end date (1 Sep 2007) added as reported by ClinicalTrials.gov record.
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.